En novembre 2012, à la suite de deux referendums, les populations des États du Colorado et de Washington approuvaient la production et la commercialisation du cannabis non médical. Ces scrutins historiques, synonymes de légalisation, allaient lancer une onde de choc à l’échelle des États-Unis et du monde, ébranlant le paradigme prohibitionniste alors en vigueur.
This Clinical Study is the First from Merck and Gilead’s Collaboration to Develop Potential Long-Acting HIV Treatment Options.
If approved, cabotegravir would be the first, long-acting therapy for HIV PrEP.
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021. Clinical Trial is Part of the Company’s HIV-1 Prevention Clinical Program Studying Islatravir as a Long-Acting PrEP Agent.
ViiV Healthcare receives Marketing Authorisation for Rukobia® (fostemsavir), a first-in-class attachmentinhibitor in combination with other antiretrovirals for the treatment of adults with multi drug-resistant HIV. Fostemsavir addresses a critical need in HIV care for those with little to no treatment options left who are at risk of further disease progression, or complications from HIV.